Tag

Exact Sciences

All articles tagged with #exact sciences

business22 days ago•28 min saved

Abbott to close Exact Sciences acquisition, expanding cancer diagnostics leadership

Abbott expects to close its acquisition of Exact Sciences on March 23, 2026 after regulatory clearances, adding Exact’s cancer-screening and precision-oncology portfolio (Cologuard, Oncotype DX, Oncodetect, Cancerguard) to expand Abbott’s diagnostics leadership. The deal is projected to bring about $3 billion of incremental sales in 2026, accelerate Abbott’s growth in diagnostics, and dilute 2026 adjusted EPS by about $0.20, as the company aims to make cancer detection and management more accessible.

via Abbott MediaRoom|

#abbott #business #cancer-screening

finance2 years ago•2 min saved

"Blood-Based Test for Colorectal Cancer Shows High Accuracy, Driving Surge in Exact Sciences Stock"

Exact Sciences stock surged to a seven-month high after Freenome revealed results of a study on its blood-based colon cancer test, which showed similar specificity but lower sensitivity compared to Exact's Cologuard. Analysts believe the results dispel concerns about blood-based tests replacing stool-based ones and expect Exact Sciences shares to trade on a fundamental basis going forward. Despite the stock's recent climb, Freenome could still improve its test's sensitivity for advanced adenomas.

via Investor's Business Daily|

#blood-based-tests #colon-cancer #exact-sciences

stock-market2 years ago•1 min saved

Cramer's Lightning Round: Caution Advised on HF Sinclair, Rivian, and Fisker

Jim Cramer advises caution with Toast due to its point-of-sale business model, warns that CVS is primarily a retailer with a healthcare business and highlights issues with theft, suggests staying away from HF Sinclair and recommends looking into other oil companies, believes Exact Sciences needs to focus on increasing earnings rather than just sales, and expresses positivity towards SoFi despite the current downward trend in banking stocks.

via CNBC|

#cvs #exact-sciences #hf-sinclair

healthcare2 years ago•3 min saved

Exact Sciences' Cologuard 2.0 trial results fail to sustain stock gains.

Exact Sciences' next-generation Cologuard, a stool-based test for colon cancer, outperformed the original test in a study of 20,000 people, with 94% sensitivity and 91% specificity. The company plans to file for approval of the new test by the end of the year. Despite the positive results, Exact Sciences' stock pulled back 4.8% at the close, settling at 89.78. However, the stock has risen 207% from its recent low point in late October.

via Investor's Business Daily|

#cologuard #colon-cancer-screening #exact-sciences